JPRN-UMIN000020701已完成未知
The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma - The efficacy and safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma
Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University0 个研究点目标入组 40 人开始时间: 2016年1月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have a severe difficulty swallowing and who are unable to take orally the tablet. Patients who are judged to be inappropriate as a subject by physicians.
研究者
相似试验
进行中（未招募）
1 期
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleEUCTR2016-001879-73-Outside-EU/EEAEisai Medical Research Inc.111
已完成
2 期
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With RabeprazoleGastroesophageal Reflux DiseaseNCT00132496Eisai Inc.111
已完成
不适用
Efficacy and safety of two weeks rabeprazole treatment for gastric ulcers after endoscopic submucosal dissection (ESD).early gastric cancer or gastric adenomaJPRN-UMIN000000688The University of Tokyo, Department of Gastroenterology55
尚未招募
Unknown
Clinical Efficacy of rabeprazole in patients treated with dual antiplatelet agents including potent P2Y12 inhibitors after percutaneous coronary intervention for acute coronary syndromeKCT0008344Yonsei University Yongin Severance Hospital50
已完成
3 期
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent SufferersHeartburnNCT00236184Eisai Inc.629